ClinicalTrials.gg
RecruitingNCT07775833Updated Sep 1, 2026

Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community

An interventional study of Golden oyster mushroom powder in Dementia and Cognitive Assessment, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 45 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Dementia with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Dementia · Singapore.

Planned enrollment
6th of 22
600 · median 225
Started
2026
with 3 others
No phase
14 of 25
6 open now
Registered
25th of 25
by date
Lead sponsor
7 of 25
National University of Singapore

Among the 25 studies in Dementia with a site in Singapore, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, and was the 25th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

7 of the 25 studies in Dementia with a site in Singapore are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Dementia with a site in Singapore, or all of them as a file.
02

Study summary

The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds.

The investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds.

Participants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance

03

Conditions studied

  • Dementia
  • Cognitive Assessment

Browse trials for

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Community-living adult aged 45 years to 80 years, AND
  • (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as "self-reported memory problems that have been getting worse over the past year.", AND
  • (3) Consume mushrooms no more than once a week, AND
  • (4) No dementia: CDR global score equal to zero.

Exclusion criteria

Exclusion Criteria:

  • (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR
  • (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR
  • (3) Significant sensory or motor impairments, OR
  • (4) Known allergy to mushrooms or a history of serious food allergies, OR
  • (5) Participants with a history of gout, OR
  • (6) Diagnosed with hyperuricemia.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    mushroom powder intervention arm

    Dietary Supplement: Golden oyster mushroom powder

  • No intervention
    Placebo arm

Interventions

  • Dietary supplementGolden oyster mushroom powder

    Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance monitored using electronic diary apps. The powder contains 7.0 mg/g of ergothioneine (dry weight).

06

What researchers measure

Primary outcomes

  1. MMSE

    Total scores change

    Time frame: 24 months

Secondary outcomes

  1. plasma ergothioneine

    Time frame: 24 months

  2. Rey Auditory Verbal Learning Test

    Time frame: 12, and 24 months

  3. inflammatory markers

    hs-CRP, TNFα, IL-1, IL-6, and etc

    Time frame: 24 months

  4. NfL

    Time frame: 24 months

  5. Epigenetic age

    Time frame: 24 months

  6. Symbol Digit Modality test

    Time frame: 12, and 24 months

  7. Clinical Dementia Rating

    Time frame: 12, and 24 months

07

Study locations

1 of 1 sites recruiting
  • Tahir Foundation Building, MD1, Level 12 (12 Science Drive 2)
    Singapore, 117549, Singapore
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 26 months is close to that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Aug 20, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07775833
Responsible party
Feng Lei (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Aug 20, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 1, 2026

Study contacts

Jiatong Shan
Contact
e1397079@u.nus.edu
+65 89413228
Kai Xuan Lim
Contact
kaixuan@nus.edu.sg
+65 90553343
Lei FEng
principal investigator · National University of Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion